Needham & Company Downgrades Theravance Biopharma (TBPH) to Hold, Following Strategic Business Update
Tweet
Share
E-mailGet Alerts TBPH Hot Sheet
Price: $16.97 +0.30%
Rating Summary:
4 Buy, 10 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 10 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company analyst Joseph Stringer downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Hold.
For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.
Shares of Theravance Biopharma closed at $8.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Needham Reiterates Buy Rating on WhiteFiber Inc (WYFI)
- Wolverine World Wide (WWW) PT Raised to $24 at Needham
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
